Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment

HIV Clinical Trials

Volumn 15, Issue 6, 2014, Pages 269-273

  McDonald, Cheryl K ^a   Martorell, Claudia ^b   Ramgopal, Moti ^c   Laplante, Francois ^d   Fisher, Martin ^e   Post, Frank A ^f   Liu, Yapei ^g   Curley, Joanne ^g   Abram, Michael E ^g   Custodio, Joseph ^g   Graham, Hiba ^g   Rhee, Martin S ^g   Szwarcberg, Javier ^g  

^a Tarrant County Infectious Disease   (United States)

^b Boston Biomedical   (United States)

^c Midway Immunology and Research Center   (United States)

^d Clinique Medicale du Quartier Latin   (Canada)

^e BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g GILEAD SCIENCES   (United States)

Author keywords

cobicistat; HIV clinical trials; renal impairment

Indexed keywords

ATAZANAVIR; COBICISTAT; CREATININE; CYSTATIN C; DARUNAVIR; RITONAVIR; VIRUS RNA; CARBAMIC ACID DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; THIAZOLE DERIVATIVE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONSTIPATION; CONVULSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLATULENCE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; OPEN STUDY; PAIN; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PROTEINURIA; RHINOPHARYNGITIS; SIDE EFFECT; SKULL FRACTURE; SUICIDAL IDEATION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CLINICAL TRIAL; COMPLICATION; HIV INFECTIONS; KIDNEY FAILURE; METABOLISM; MIDDLE AGED;

ADULT; AGED; CARBAMATES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; THIAZOLES;

EID: 84916237763     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1506-269     Document Type: Article

References (7)

1. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus coformulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012; 379: 2439-2448.
2. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012; 379: 2429-2438.
3. Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment- naive HIV type 1-infected patients: Week 48 results. J Infect Dis. 2013;208:32-39.
4. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145: 247-254.
5. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150: 604-612.
6. Stevens LA, Levey AS. Current status and future perspectives for CKD testing. Am J Kidney Dis. 2009;53:S17-26.
7. German P. Pharmacokinetics of elvitegravir and cobicistat in subjects with severe renal impairment. Presented at 13th International Workshop on Clinical Pharmacology of HIV Therapy; April 16-18, 2012; Barcelona, Spain. Poster 38.